Company Filing History:
Years Active: 2022
Title: The Innovations of Phillip Lazzara
Introduction
Phillip Lazzara is an accomplished inventor based in Chicago, IL. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target specific protein interactions. His work has the potential to impact the treatment of various diseases.
Latest Patents
Lazzara holds a patent for "1,4-substituted isoquinoline inhibitors of KEAP1/NRF2 protein-protein interaction." This patent discloses compounds that can act as inhibitors of the Kelch-like ECH-associated protein 1/nuclear factor (erythroid-derived 2)-like 2 (KEAP1/NRF2) protein-protein interaction. The compounds are designed to treat and prevent diseases such as COPD, multiple sclerosis, and diabetes, as well as promote wound healing. The patent includes compounds of Formula (I) and pharmaceutically acceptable salts thereof, with specific substituents described in detail.
Career Highlights
Phillip Lazzara is affiliated with the University of Illinois, where he conducts research and collaborates with other experts in the field. His innovative work has led to advancements in therapeutic strategies for chronic diseases.
Collaborations
Lazzara has worked alongside notable colleagues, including Terry D Moore and Brian J David. Their combined expertise enhances the research efforts at the University of Illinois.
Conclusion
Phillip Lazzara's contributions to medicinal chemistry and his innovative patent demonstrate his commitment to advancing healthcare solutions. His work continues to pave the way for new treatments that can improve patient outcomes.